Salivary β2-microglobulin levels in patients with erosive oral lichen planus and squamous cell carcinoma

• Main Authors: Fatemeh Nosratzehi, Tahereh Nosratzehi, Ebrahim Alijani, Soha Saberi Rad
• Format: Article
• Language: English
• Published: BMC 2020-06-01
• Series: BMC Research Notes
• Subjects: Salivary β2-microglobulin; SCC; OLP
• Online Access: http://link.springer.com/article/10.1186/s13104-020-05135-w

Abstract Objectives β2 microglobulin, as a biomarker, is used for the diagnosis of oral malignant and pre-malignant lesions. The components of the microglobulin system can directly or indirectly help grow and develop tumors. The present study aims to compare beta-2 microglobulin levels in patients with lichen planus of the esophagus, oral squamous cell carcinoma, and healthy individuals. Further, it evaluated the salivary β2-microglobulin level in malignant and pre-malignant lesions. Oral lichen planus (OLP) is a chronic skin-mucus disorder. Of the total 75 patients referred to Oral Medicine at Dentistry School of Zahedan University of Medical Sciences, 25 were healthy and 25 had oral lichen planus (OLP) and the rest had squamous cell carcinoma (SCC). To collect the saliva samples, unstimulated spitting was used. They were collected between 9 and 12 a.m. Salivary beta2 microglobulin was recorded based on the factory instructions by ELISA optical density method with 450 nm wavelength for each sample. The data were analyzed using descriptive, Kruskal–Wallis and Mann–Whitney and Pearson’s correlation coefficient (SPSS 21). Results The salivary β2 microglobulin level in patients with squamous cell carcinoma (SCC) and oral lichen plan (OLP) is significantly higher than that in healthy group. Thus, this index is used for assessing early malignant transformation and oral pre-malignant lesion.